Abstract
A systematic characterization of the genetic alterations driving ALCLs has not been performed. By integrating massive sequencing strategies, we provide a comprehensive characterization of driver genetic alterations (somatic point mutations, copy number alterations, and gene fusions) in ALK(-) ALCLs. We identified activating mutations of JAK1 and/or STAT3 genes in ∼20% of 88 [corrected] ALK(-) ALCLs and demonstrated that 38% of systemic ALK(-) ALCLs displayed double lesions. Recurrent chimeras combining a transcription factor (NFkB2 or NCOR2) with a tyrosine kinase (ROS1 or TYK2) were also discovered in WT JAK1/STAT3 ALK(-) ALCL. All these aberrations lead to the constitutive activation of the JAK/STAT3 pathway, which was proved oncogenic. Consistently, JAK/STAT3 pathway inhibition impaired cell growth in vitro and in vivo.
Copyright © 2015 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Activating Transcription Factor 3 / genetics
-
Activating Transcription Factor 3 / metabolism
-
Animals
-
Cell Line, Tumor
-
Gene Expression Regulation, Neoplastic*
-
HEK293 Cells
-
Humans
-
Janus Kinase 1 / genetics
-
Lymphoma, Large-Cell, Anaplastic / genetics*
-
Mice
-
Mutant Chimeric Proteins / genetics
-
Mutant Chimeric Proteins / metabolism
-
NF-kappa B / genetics
-
Phosphorylation
-
Proto-Oncogene Proteins / genetics
-
Receptor Protein-Tyrosine Kinases / genetics
-
STAT3 Transcription Factor / genetics
-
STAT3 Transcription Factor / metabolism*
-
Signal Transduction
-
TYK2 Kinase / genetics
Substances
-
Activating Transcription Factor 3
-
Atf3 protein, mouse
-
Mutant Chimeric Proteins
-
NF-kappa B
-
Proto-Oncogene Proteins
-
STAT3 Transcription Factor
-
Stat3 protein, mouse
-
Receptor Protein-Tyrosine Kinases
-
Ros1 protein, mouse
-
Jak1 protein, mouse
-
Janus Kinase 1
-
TYK2 Kinase
-
Tyk2 protein, mouse